WebMerck (MSD) has agreed to acquire all the outstanding shares of Acceleron Pharma for $11.5bn in cash. The deal will help Merck gain access to Acceleron’s lead therapeutic candidate, sotatercept. Credit: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved. Subscribe to our email newsletter Web29 okt. 2024 · As previously announced on October 12, 2024, Merck commenced, through a subsidiary, Astros Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Acceleron ...
Merck signs agreement to buy Acceleron Pharma for $11.5bn
Web30 sep. 2024 · Merck & Co is buying Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue. The deal gives Merck access to Acceleron's rare disease drug candidate, sotatercept, ... Web30 sep. 2024 · September 30, 2024 at 05:56 pm (Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue. horaires imsak ramadan 2021 paris
Merck To Buy Acceleron For $11.5B - Competition Policy International
WebMerck has placed lofty ambitions on sotatercept and is applying development strategies learned growing Keytruda. (Photo by Kena Betancur/Getty Images) A year after dolling out $11.5 billion to... Web18 nov. 2024 · Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck’s pending acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN) expired at 11:59 p.m., Eastern … Web8 okt. 2024 · First, there were rumors that Merck (MRK 0.38%) might acquire Acceleron Pharma . Then those rumors were confirmed, with the big pharma company announcing … fbl okmány